JESSICA GAUBERT: Open Payments
NPI 1942830682 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,468 in 29 payments from 7 companies in 2025. Trend: 2023 $861 · 2024 $1,450 · 2025 $1,468
Long term medical supply or device loan: $1,000Food & beverage: $468
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $1,073 |
| Merck Sharp & Dohme LLC | 5 | $200 |
| Celgene Corporation | 3 | $63 |
| Daiichi Sankyo Inc. | 2 | $57 |
| PFIZER INC. | 2 | $33 |
| Fennec Pharmaceuticals, Inc. | 1 | $25 |
| Gilead Sciences, Inc. | 1 | $18 |
Products named: KISQALI, KEYTRUDA, REBLOZYL, Enhertu, Fabhalta, IBRANCE, Fyarro, Trodelvy.
Industry payments across LA — which companies pay providers there.
